evipedia.ai
← Back

Calcium Alpha-Ketoglutarate for Health & Longevity

Evidence Review created on 09/07/2026 using AI4L / Opus 5

Also known as: Ca-AKG, CaAKG, AKG-Ca, dAKG, Calcium 2-Oxoglutarate, Alpha-Ketoglutaric Acid Calcium Salt

Motivation

Calcium alpha-ketoglutarate is a stable salt form of a molecule the body makes constantly as part of the chemical cycle that turns food into cellular energy. The same molecule supplies raw material for building certain amino acids and collagen, and helps enzymes that switch genes on and off. Blood levels fall steeply with age, and that decline is what turned a long-familiar sports and hospital nutrition ingredient into a candidate longevity supplement.

The compound has a long practical history. Doctors used it in the 1960s to lower blood ammonia, in kidney units to bind excess phosphate, and in surgical wards to slow muscle breakdown after operations. Interest in ageing arrived later, after feeding studies in worms and mice reported longer life and less frailty, and after a commercial dataset suggested users looked biologically younger. Larger, independent animal work has since failed to reproduce the survival effect.

This review examines how calcium alpha-ketoglutarate is thought to work, what human studies have and have not measured, how much of the evidence rests on the calcium it carries rather than on the alpha-ketoglutarate itself, and where the trials now under way may settle the question.

Benefits - Risks - Protocol - Conclusion

High-level overviews of calcium alpha-ketoglutarate from expert platforms and narrative reviews, selected for depth on the compound itself rather than passing mention.

Priority-platform note: searches of hubermanlab.com, chriskresser.com and lifeextension.com returned no article, episode or magazine feature devoted to alpha-ketoglutarate — only incidental mentions inside pieces on other subjects — so nothing from those three platforms met the depth requirement above.

Grokipedia

  • Calcium alpha-ketoglutarate

    Dedicated article on the calcium salt itself: chemistry, Krebs cycle role, the mouse lifespan figures, human trial evidence, and a safety, dosage and regulatory section absent from most consumer summaries.

Examine

  • Alpha-Ketoglutarate

    Independent evidence grading with a dosage page (3.6–6 grams in research), a drawbacks entry separating plain alpha-ketoglutarate from the arginine salt, and a dedicated question on whether it prolongs healthy lifespan.

ConsumerLab

  • Does AKG Extend Lifespan and Slow Aging?

    The only consumer-testing coverage of AKG (alpha-ketoglutarate): distinguishes the calcium salt from delayed-release forms, compares marketed products and cost, and concludes that good clinical evidence for human lifespan or healthspan is lacking.

Systematic Reviews

Systematic reviews and meta-analyses bearing on calcium alpha-ketoglutarate, covering both its best-documented clinical use and the principal hazard carried by its mineral component.

Coverage note: only one of the five papers examines alpha-ketoglutarate itself; the other four characterise the calcium load the salt carries, with both sides of the cardiovascular question represented. The claimed benefit side of the trade-off is unrepresented: as of 07/09/2026 no systematic review or meta-analysis examines alpha-ketoglutarate in any form for ageing, healthspan or longevity outcomes, because the underlying randomised evidence does not yet exist. The US Preventive Services Task Force is a government-appointed panel whose members derive no revenue from the conclusions it publishes.

Mechanism of Action

Alpha-ketoglutarate sits at the centre of the tricarboxylic acid cycle (the Krebs cycle, the mitochondrial sequence that extracts energy from food). Isocitrate dehydrogenase makes it; the alpha-ketoglutarate dehydrogenase complex consumes it, a rate-limiting control point for the cycle.

Three roles matter for ageing. It is the obligatory partner of the 2-oxoglutarate-dependent dioxygenases — the ten-eleven translocation (TET) enzymes that strip methyl marks from DNA, the Jumonji-C histone demethylases that do the same on chromatin proteins, and the prolyl hydroxylases that mature collagen and tag HIF-1α (hypoxia-inducible factor 1-alpha, the low-oxygen master switch) for destruction. It is transaminated to glutamate and glutamine, scavenging ammonia. And it binds the beta subunit of ATP synthase, the enzyme that makes the cell’s energy currency, adenosine triphosphate.

The mechanistic accounts compete. Chin and colleagues showed that ATP synthase inhibition lowers cellular energy and suppresses TOR (target of rapamycin, the nutrient-sensing growth pathway), partly reproducing dietary restriction in nematodes. The mouse lifespan study found no drop in mTORC1 (the main growth-driving complex of that pathway) signalling in any tissue and traced benefit instead to interleukin-10 (an anti-inflammatory immune messenger) released by T cells. A third reading is that the calcium carrier did the work: that study’s control diet had no calcium.

The anion itself is short-lived — under five minutes in pig plasma — heavily oxidised in the gut wall on first pass, moved by mitochondrial and kidney dicarboxylate transporters, and cleared by the cycle, not by liver drug-metabolising enzymes; the calcium follows ordinary handling.

Historical Context & Evolution

Alpha-ketoglutarate was identified in 1937 as an intermediate of the citric acid cycle, work for which Hans Krebs later received a Nobel Prize. Its first therapeutic use was unrelated to ageing: French clinicians gave the calcium salt orally in the 1960s to lower blood ammonia, and German nephrologists later used it for decades as a phosphate binder in dialysis, where three years of dosing normalised parathyroid hormone and a year of dosing raised plasma arginine in malnourished patients.

A second strand came from Scandinavian surgical nutrition in the late 1980s, where alpha-ketoglutarate was tested as a stable stand-in for glutamine in post-operative feeding. A third strand was commercial: arginine alpha-ketoglutarate became a mass-market pre-workout ingredient, and an eight-week randomised trial reported modest strength gains with no safety signal, which normalised gram-scale oral dosing.

The longevity framing is recent. Nematode lifespan extension in 2014 was followed in 2020 by the mouse study using the calcium salt specifically, which prompted commercialisation and, a year later, a retrospective biological-age analysis co-authored by the product’s makers. Opinion has not simply consolidated behind that picture. The multi-site Interventions Testing Program has since tested alpha-ketoglutarate twice in genetically heterogeneous mice, at two different starting ages, and found no survival benefit either time. Both results stand on the record: the original finding was in one inbred strain with a calcium-free control diet, the null results in a different genetic background at a different dose form, and neither design has yet been reconciled with the other.

Expected Benefits

Benefits are framed for a proactive, risk-aware adult who is prepared to run a multi-year protocol, monitor biomarkers and accept an unfinished evidence base — not for a general population expecting a settled recommendation.

High 🟩 🟩 🟩

Phosphate Lowering in Dialysis-Dependent Kidney Disease

Two randomised crossover trials in haemodialysis patients found the salt lowered serum phosphate — a marker tied to mortality in kidney failure — as effectively as the standard binders it was tested against: against calcium acetate in 28 patients and against calcium carbonate in 19. An uncontrolled series of fourteen patients dosed for three years adds that hyperparathyroidism (an overactive parathyroid gland, which drives bone loss in kidney failure) resolved in every patient without vitamin D. All the evidence is in dialysis, not in healthy adults.

Magnitude: Serum phosphate fell from 2.47 to 1.95 mmol/L by week 4 against calcium acetate (p = 0.0001); over 36 months in the uncontrolled series it fell from 2.6 to 1.9 mmol/L and intact parathyroid hormone from 29 to 8 pmol/L (both p < 0.001).

Medium 🟩 🟩

Reduced Bone Resorption in Postmenopausal Osteopenia

A six-month double-blind randomised trial in 76 postmenopausal women with osteopenia (thinner-than-normal bone) compared the salt against the same calcium dose alone. Serum C-terminal telopeptide of type I collagen (CTX, a standardised marker of how fast bone is being broken down) fell substantially in the salt group and differed significantly from the calcium-only arm at 12 and 24 weeks. Lumbar-spine bone mineral density rose slightly from baseline but the between-group difference was not statistically significant. Osteocalcin, a bone-formation marker, did not move. No trial has replicated this.

Magnitude: Mean serum CTX fell 37% from baseline by week 24 (p = 0.006) at 6 grams of alpha-ketoglutarate plus 1.68 grams of calcium daily; lumbar-spine bone mineral density differed by only 0.9% between arms, which was not significant.

Low 🟩

Preserved Muscle Protein Synthesis After Surgical Trauma ⚠️ Conflicted

In 21 patients after gallbladder surgery, adding alpha-ketoglutarate to intravenous feeding prevented the fall in muscle polyribosomes and free glutamine and cut cumulative nitrogen loss substantially. A later randomised trial of tube feeding after abdominal surgery found no effect. Net reading: the benefit appears route-dependent and unconfirmed.

Magnitude: Cumulative nitrogen balance over three post-operative days was −2.6 grams with alpha-ketoglutarate versus −9.9 grams without (p < 0.05); polyribosome concentration fell 25.8% in controls and did not fall in the treated group.

Reduction of Blood Ammonia

The oldest clinical use: French clinicians reported in 1964 that oral dosing lowered raised blood ammonia, the anion being transaminated to glutamate and glutamine and so fixing free nitrogen. That report is an uncontrolled case series, never replicated in any population.

Magnitude: Not quantified in available studies. The 1964 report predates structured outcome reporting, and no controlled trial has since measured blood ammonia on the calcium salt.

Accelerated Wound Healing in Burn Injury

A systematic review of fifteen burn studies reported faster wound closure with alpha-ketoglutarate, delivered mostly as its ornithine dipeptide, through enhanced collagen synthesis, a step whose prolyl hydroxylases require it. Cohorts were small and heterogeneous, and the calcium salt was not the form tested.

Magnitude: Direction is consistently positive for wound closure and collagen deposition across the fifteen included studies, but the review reports no pooled outcome figure, because the cohorts were too small and heterogeneous to combine.

Reduced Heart-Muscle Injury During Bypass Surgery

Alpha-ketoglutarate added to the solution that stops the heart during bypass surgery cut markers of heart-muscle damage in a randomised trial of 24 men, through better oxygen use. A companion trial found higher renal blood flow. Evidence is indirect: the dose went into the coronary circulation, not by mouth.

Magnitude: Four hours after the clamp came off, creatine kinase MB was 32 against 49 micrograms per litre in controls and troponin T 1.1 against 2.0, at 28 grams of alpha-ketoglutarate added to the perfusion solution.

Speculative 🟨

Lower Epigenetic Age Estimates ⚠️ Conflicted

An uncontrolled series of 42 users reported eight years off DNA methylation age; a 4,260-person cohort found 1.8. The product maker co-authored the first, the test seller both. Net reading: uncontrolled commercial data only.

Lifespan Extension and Compression of Frailty ⚠️ Conflicted

Mice given the salt from 18 months lived longer and spent less of life frail. The multi-site Interventions Testing Program saw no lifespan effect at two starting ages. Net reading: unreplicated animal evidence.

In 28-month-old female mice the salt blocked the age-related rise across 24 serum cytokines and raised T-cell interleukin-10. Male mice showed no cytokine change. No human inflammatory marker data have been published.

Protection Against Vascular Calcification

Alpha-ketoglutarate reduced aortic mineral deposition in kidney-disease rats and mice and in human artery rings, acting through the ten-eleven translocation 2 enzyme. No human dosing study has measured arterial calcium.

Preservation of Muscle Mass and Grip Strength in Ageing

In a chemically aged mouse model, alpha-ketoglutarate improved muscle mass, grip strength and endurance by restoring protein turnover and mitochondrial function. Evidence is animal-only; no human trial has measured strength on this compound.

Reduced Fat Gain and Better Glucose Tolerance

Alpha-ketoglutarate cut body-weight gain and fat mass and improved glucose tolerance in middle-aged mice on a high-fat diet, by demethylating the Prdm16 promoter and restoring beige fat formation. Evidence is animal-only.

Preservation of Ovarian Reserve and Egg Quality

Four months of alpha-ketoglutarate raised follicle numbers and improved egg quality in ageing mice, lowering oxidative damage and abnormal spindle assembly. Evidence is animal-only; no human fertility or reproductive-ageing endpoint has been measured.

Synaptic and Cognitive Protection

Alpha-ketoglutarate restored synaptic plasticity in an Alzheimer’s mouse model and slowed neuronal ageing in oxidative-stress cell work through the same growth pathway. No human cognitive endpoint has been tested.

Benefit-Modifying Factors

  • Baseline plasma alpha-ketoglutarate: circulating levels fall roughly tenfold between ages 40 and 80, as noted in the mouse lifespan study’s discussion. Repletion logic predicts most benefit in the depleted, but no assay is clinically available to identify them.

  • Baseline epigenetic age acceleration: the human trial deliberately enrolled only people whose DNA methylation age exceeded their chronological age, on the reasoning that a clock already at par has no room to fall. Enrolment data confirmed 80.2% of enrolled participants were biologically older.

  • Sex: in mice, survival benefit was statistically significant only in females, and the interleukin-10 mechanism was female-specific; male median lifespan rose 9.6–12.8% without reaching significance. Commercial formulations are sold as separate male and female versions on this basis.

  • Genetic variation in the target enzymes: loss-of-function variants in the ten-eleven translocation 2 gene (which uses alpha-ketoglutarate to demethylate DNA) abolished the anti-calcification effect in knockout mice, suggesting carriers of somatic clonal variants may respond less.

  • Pre-existing conditions: the clearest human signals came from populations with a specific deficit — dialysis patients with phosphate retention, postmenopausal women with accelerated bone turnover, patients in post-surgical catabolism. Metabolically healthy adults have no comparable documented deficit to correct.

  • Age at initiation: the mouse benefit appeared with a late start at 18 months, but the Interventions Testing Program found nothing starting at either 7 or 18 months, so the relevant window is unresolved — directly relevant at the older end of the target range.

  • Dietary calcium intake: because the salt supplies calcium, benefit attributable to alpha-ketoglutarate itself is hardest to separate in people whose habitual calcium intake is low, and the mouse study’s control diet contained no calcium at all.

Potential Risks & Side Effects

Risks are framed for an adult who will be dosing for years, stacking other supplements, and monitoring labs — not for a short-course user under clinical supervision.

High 🟥 🟥 🟥

No risk reaches High: no human clinical endpoint or validated clinical surrogate harm has been attributed to calcium alpha-ketoglutarate in more than one trial, because no safety-powered randomised trial of the compound has reported.

Medium 🟥 🟥

Kidney Stones and Hypercalciuria from the Calcium Load

Every gram of the salt carries about 218 milligrams of elemental calcium, so a two-gram protocol adds roughly 435 milligrams on top of diet. Pooled randomised trials of supplemental calcium taken with vitamin D show a small but statistically significant excess of kidney stones over two to seven years; calcium alone in three smaller trials showed none. The mechanism is hypercalciuria (excess calcium in the urine). This is an extrapolation: no stone data exist for the alpha-ketoglutarate salt itself, which raised serum calcium less than calcium acetate in dialysis.

Magnitude: Absolute risk difference for kidney stones with calcium plus vitamin D was +0.33% (95% confidence interval 0.06% to 0.60% — the range in which the true value most likely lies) across three trials in 39,213 adults; with calcium alone it was 0.00% (−0.87% to 0.87%) in 1,259 adults.

Gastrointestinal Intolerance

Acid-load and osmotic effects produce nausea, vomiting, loose stools or abdominal discomfort at gram doses; the calcium fraction can instead cause constipation. In a randomised crossover trial of the salt in haemodialysis, intolerance forced withdrawal within one to two weeks, and every affected patient had pre-existing gastrointestinal symptoms. A randomised trial of alpha-ketoglutarate-enriched tube feeding after abdominal surgery reported restricted tolerance that limited delivery. No dose-response data exist in healthy adults.

Magnitude: Five of 17 patients (29%) withdrew within one to two weeks for anorexia, vomiting, diarrhoea or general uneasiness at gram-scale oral dosing; the remaining 12 reported no side effects at all.

Low 🟥

Cardiovascular Events Attributed to Supplemental Calcium ⚠️ Conflicted

Patient-level pooling of five calcium trials found more heart attacks on supplements; a 2023 pooled analysis of randomised trials and an updated systematic review found nothing. Doses were about one gram of calcium, roughly double what a typical protocol adds. Net reading: a bounded, unresolved signal, not a demonstrated harm.

Magnitude: Hazard ratio 1.31 (a 31% higher rate of events over time; 95% confidence interval 1.02 to 1.67) for myocardial infarction (heart attack) in the patient-level pooling, against relative risk 1.15 (the ratio of event rates between the two groups; 0.88 to 1.51) in the 2023 pooled trials, which excluded any excess coronary or stroke risk above 0.3–0.5% per year.

Preformed Vitamin A Exposure in Combination Products

The best-studied branded formulation pairs the salt with preformed vitamin A in its male version. Swedish cohort data link the highest serum retinol quintile to a sharply raised hip-fracture rate. The salt alone carries no such exposure, so this is a formulation risk, not a compound risk.

Magnitude: In that cohort the highest quintile of serum retinol carried a rate ratio of 1.64 (events per person-year relative to the comparison group; 95% confidence interval 1.12 to 2.41) for any fracture and 2.47 (1.15 to 5.28) for hip fracture, versus the middle quintile.

Speculative 🟨

Metabolic Support of Glutamine-Dependent Tumours ⚠️ Conflicted

In cell work alpha-ketoglutarate stabilises MYC, a growth-driving cancer protein, and can feed glutamine-addicted tumours; it restores gene-regulating enzyme activity that mutations suppress in glioma (a brain tumour). Net reading: context-dependent and untested in people.

Blunted Training Adaptation

Because the molecule inhibits ATP synthase and can lower the growth pathway that drives muscle protein synthesis, a theoretical concern is dampened muscle growth when dosed around resistance training. No human study has tested this.

Ocular Changes Seen in Treated Mice

Cataract and corneal opacity occurred more often in treated mice than controls in the lifespan study, though neither difference reached significance. The basis is a single animal observation with no human follow-up.

Risk-Modifying Factors

  • Calcium-sensing receptor variants: inactivating CASR mutations (the gene encoding the receptor that tells the parathyroid gland how much calcium is in blood) cause familial hypocalciuric hypercalcaemia (excess blood calcium), in which any added calcium load raises serum calcium disproportionately.

  • Baseline urinary and serum calcium: a 24-hour urinary calcium already above 250 milligrams, or an albumin-corrected serum calcium in the upper decile, converts a modest supplemental load into a real stone and hypercalcaemia risk.

  • Baseline vitamin D status: 25-hydroxyvitamin D above roughly 50 ng/mL markedly increases fractional calcium absorption, which is why the kidney-stone excess in the pooled trials appeared with calcium plus vitamin D and not calcium alone.

  • Sex: postmenopausal women carry higher background stone and vascular-calcification exposure and are the group most likely to already be taking a separate calcium supplement, so cumulative load rather than this product alone is the relevant quantity.

  • Kidney function: at an estimated glomerular filtration rate (a calculated measure of kidney filtering capacity) below 60 mL/min/1.73 m², phosphate binding and calcium retention both change, shifting the compound from supplement to a therapy needing supervision.

  • Pre-existing conditions: primary hyperparathyroidism, sarcoidosis and other granulomatous disease (inflammatory disorders that form nodules and switch on vitamin D), active nephrolithiasis (kidney stone disease), and digoxin therapy each convert a tolerated calcium load into a clinically consequential one.

  • Age: arterial calcification burden and stone recurrence both rise steeply after 65, so the same milligram load carries more consequence at the older end of the target range than in midlife.

Key Interactions & Contraindications

  • Levothyroxine (thyroid hormone replacement): calcium chelates it in the gut and reduces absorption. Severity: caution. Consequence: under-replacement and rising thyroid-stimulating hormone. Mitigation: dosing is separated by at least four hours, with thyroid labs rechecked after six weeks.

  • Tetracyclines and fluoroquinolones (doxycycline, minocycline, ciprofloxacin, levofloxacin): calcium forms insoluble complexes with both classes. Severity: caution. Consequence: treatment failure from sub-therapeutic antibiotic levels. Mitigation: dosing is separated by two hours before or four to six hours after the antibiotic.

  • Oral bisphosphonates (alendronate, risedronate, ibandronate): calcium blocks their already poor absorption. Severity: caution. Consequence: loss of anti-fracture efficacy. Mitigation: the bisphosphonate is taken fasted on waking, with the salt delayed by at least 60 minutes.

  • Thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide): these reduce urinary calcium excretion. Severity: monitor. Consequence: hypercalcaemia with nausea, confusion or arrhythmia. Mitigation: albumin-corrected serum calcium is checked at six weeks and then annually.

  • Digoxin: raised serum calcium potentiates cardiac glycoside toxicity. Severity: absolute contraindication without cardiology oversight. Consequence: life-threatening ventricular arrhythmia. Mitigation: the combination is avoided, or serum calcium and digoxin levels monitored under specialist supervision.

  • Over-the-counter calcium-carbonate antacids and calcium-fortified products: additive elemental calcium. Severity: caution. Consequence: exceeding the 2,000–2,500 milligram daily upper intake level, raising stone risk. Mitigation: all sources are totalled before dosing and combined intake capped at 2,000 milligrams.

  • Over-the-counter iron salts (ferrous sulfate, ferrous bisglycinate): calcium competes for the same divalent transporter. Severity: monitor. Consequence: blunted iron repletion and persistent low ferritin. Mitigation: dosing is separated by two hours, with iron taken alongside vitamin C on an empty stomach.

  • Supplemental vitamin D3 and vitamin K2: vitamin D increases calcium absorption, which is additive rather than antagonistic. Severity: monitor. Consequence: hypercalciuria and stone formation at high combined doses. Mitigation: 25-hydroxyvitamin D is held at 40–60 ng/mL rather than higher, and paired with vitamin K2.

  • Other alpha-ketoglutarate salts (arginine, ornithine) and magnesium or zinc supplements: the first two stack the same anion, the latter two compete for absorption. Severity: caution. Consequence: unintended total dose, or blunted magnesium and zinc status. Mitigation: all alpha-ketoglutarate sources are counted, and minerals dosed separately.

  • Other longevity interventions that suppress the growth pathway (rapamycin, metformin, extended fasting): additive suppression of the same nutrient-sensing signal. Severity: caution. Consequence: unpredictable compounding, and impaired training adaptation. Mitigation: agents are introduced one at a time with at least eight weeks between additions.

Populations who should avoid calcium alpha-ketoglutarate:

  • Hypercalcaemia of any cause, or albumin-corrected serum calcium above 10.5 mg/dL (2.62 mmol/L)
  • Primary hyperparathyroidism, diagnosed or suspected on a raised calcium with non-suppressed parathyroid hormone
  • Active nephrolithiasis, or two or more calcium-containing stones in the preceding five years
  • Granulomatous disease with unregulated vitamin D activation — sarcoidosis, tuberculosis, histoplasmosis
  • Chronic kidney disease stage 4 or 5 (estimated glomerular filtration rate below 30 mL/min/1.73 m²) outside nephrology supervision
  • Isocitrate dehydrogenase 1 or 2 mutant glioma or acute myeloid leukaemia, particularly on targeted inhibitors such as ivosidenib or enasidenib
  • Pregnancy and lactation, on absence of any safety data rather than on evidence of harm
  • People under 18, for whom no dosing or safety data exist

Risk Mitigation Strategies

  • A calcium ceiling set first: total dietary plus all supplemental calcium stays below 2,000 milligrams daily, counting the roughly 218 milligrams each gram of the salt contributes, keeping the stone and hypercalcaemia risks described above within the studied range.

  • Baseline stone screen before starting: albumin-corrected serum calcium, a 24-hour urinary calcium and a renal ultrasound in anyone with a personal or first-degree family stone history, to avoid loading calcium onto an undiagnosed stone-former.

  • Titration from a half dose: protocols start at 500–1,000 milligrams daily for two weeks before moving to the full dose, which lets gastrointestinal intolerance declare itself at a level that is easy to stop.

  • Dosing with food and fluid: the salt is taken with a meal and at least 500 mL of water, spread across the day. This lowers peak urinary calcium after each dose and reduces nausea and loose stools.

  • Separation from chelation-sensitive drugs: levothyroxine, bisphosphonates, tetracyclines, fluoroquinolones and iron are scheduled at least two to four hours away from every dose, preventing the treatment failures listed in the interactions section.

  • The plain salt rather than a vitamin-loaded combination: choosing the plain salt removes the preformed vitamin A exposure entirely and lets vitamin A and D intake be set independently against measured blood levels.

  • Calcium chemistry rechecked at six weeks and annually: serum calcium, parathyroid hormone, 25-hydroxyvitamin D and estimated glomerular filtration rate, with dosing stopped if corrected calcium exceeds 10.5 mg/dL or filtration falls more than 10% from baseline.

Therapeutic Protocol

  • Standard protocol: 1,000 mg of the salt twice daily is common consumer practice; Ponce de Leon Health’s Rejuvant, the product behind the biological-age data, gives 1,000 mg once daily, as does the ABLE trial.

  • Competing approach — plain immediate-release powder: bulk alpha-ketoglutarate at 3.6–6 grams daily is the dose range used in the surgical, burns and bone literature, and is what the Scandinavian and Polish clinical groups actually studied.

  • Competing approach — surgical and renal dosing: 4.5 grams daily as a soluble salt was the dialysis phosphate-binding protocol; the AEGIS surgical trial uses 1 gram daily perioperatively. Neither is framed as the default.

  • Best time of day: no chronobiology data exist. Dosing with breakfast and dinner is standard practice because it improves tolerance and spreads the calcium load rather than because any timing effect has been shown.

  • Half-life: the anion clears from plasma in under five minutes in pig pharmacokinetics, with heavy first-pass oxidation in the gut wall. This short exposure is the entire rationale for delayed and sustained-release tablets.

  • Single versus split dosing: split dosing is standard for the immediate-release salt because of the short half-life and to blunt the post-dose rise in urinary calcium. Sustained-release tablets are given once daily by design.

  • Genetic considerations: no pharmacogenetic testing is established. CASR variants causing familial hypocalciuric hypercalcaemia and somatic ten-eleven translocation 2 variants are the two plausible modifiers, neither validated for dose selection.

  • Sex-based differences: commercial products are split into male and female versions, but that split reflects the added vitamin, not the salt. The female-specific survival effect in mice has no human dosing counterpart.

  • Age considerations: older adults have lower endogenous levels and are the population the mouse work modelled, but also carry higher stone and vascular-calcification exposure. No dose reduction is established for the older end of the target range.

  • Baseline biomarkers influencing response: the human trial restricted entry to people whose DNA methylation age exceeded chronological age, implying dose is less relevant than selecting people with measurable room to improve.

  • Pre-existing conditions: osteopenia, dialysis-dependent kidney disease and post-surgical catabolism are the three states where a dose-response has actually been observed; healthy midlife adults are extrapolating from those settings.

Discontinuation & Cycling

  • Intended duration: framed as an open-ended daily intervention rather than a course. The registered human trials run six months of dosing plus three months of follow-up, so no evidence describes multi-year continuous use.

  • Withdrawal effects: none documented. The anion is an endogenous metabolite with a plasma half-life of minutes, so no physiological dependence or rebound mechanism is plausible, and none has been reported in dialysis series lasting three years.

  • Tapering: not required. Stopping abruptly is the approach used at the end of every clinical study, and the follow-up phase of the human trial exists to detect reversal of the biomarker, not withdrawal symptoms.

  • Cycling for efficacy: no tolerance or receptor downregulation has been described, so there is no efficacy argument for cycling. The argument that does exist is for periodic breaks to reduce cumulative calcium exposure.

  • Practical stopping trigger: discontinuation follows an albumin-corrected serum calcium above 10.5 mg/dL, a new stone, or a tracked marker that has not moved after two consecutive measurements twelve months apart.

Sourcing and Quality

  • Purity specification: material specified at 98% or higher calcium alpha-ketoglutarate is the grade used in the branded product and quoted by the main independent sellers. Below that, the remainder is unspecified process residue.

  • Third-party certificate of analysis: the meaningful document is a batch-specific certificate covering identity, assay and heavy metals (lead, cadmium, arsenic, mercury), issued by a laboratory independent of the manufacturer, not a supplier’s own in-house sheet.

  • Elemental calcium disclosure: informative labels state elemental calcium per serving, not only salt weight. Products that omit it make it impossible to total the daily calcium load against the 2,000-milligram ceiling.

  • Form selection: immediate-release capsules, delayed-release and sustained-release tablets are all sold. Only the sustained-release form is being tested in the human trial; the biological-age signal was confined to a delayed-release product.

  • Reputable suppliers: ProHealth Longevity and Renue by Science are the two brands ConsumerLab names as typical calcium alpha-ketoglutarate sellers; Toniiq, partiQlar and Vitality Pro publish batch certificates at 98–99% purity; Rejuvant from Ponce de Leon Health is the patented controlled-release product.

  • The wrong salt: arginine alpha-ketoglutarate and ornithine alpha-ketoglutarate are cheaper, far more widely stocked, and are not the compound studied for ageing. Only a label reading calcium alpha-ketoglutarate identifies the right one.

  • Manufacturing standards: the available quality signals are production in facilities audited to current good manufacturing practice and, where present, an NSF or USP mark, since no compound-specific certification programme exists for this ingredient.

Practical Considerations

  • Time to effect: no symptomatic effect should be expected. The bone-marker change took 12 weeks to separate from control, the biological-age series averaged seven months of use, and the human trial reads out at six months.

  • Common pitfall — buying the arginine form: most retail shelf space belongs to arginine alpha-ketoglutarate pre-workouts, which share the anion but not the evidence base and carry their own reports of palpitations and dizziness.

  • Common pitfall — ignoring total calcium: users frequently stack this on top of an existing calcium supplement, a calcium-fortified diet and high-dose vitamin D, pushing combined intake past the tolerable upper level without noticing.

  • Common pitfall — over-reading a methylation clock: commercial epigenetic-age tests carry several years of measurement noise, so a single favourable retest after starting is not evidence the protocol is working.

  • Regulatory status: sold in the United States as a dietary supplement, not an approved drug, with no authorised health claim; the ABLE trial protocol describes calcium alpha-ketoglutarate as holding generally recognised as safe (GRAS) status.

  • Cost and accessibility: widely available without prescription. Generic capsules run roughly US$25–45 monthly at 2 grams daily; patented controlled-release products cost two to three times that. No insurer reimburses either, so no institutional payer has a financial stake in its adoption.

Interaction with Foundational Habits

  • Sleep: direction is none, on current evidence. No stimulant or sedative property has been described, no trial has measured sleep, and the plasma half-life of minutes makes an evening dose implausible as a sleep disruptor. Practical point: dose timing can be set entirely by tolerance and drug separation rather than by sleep.

  • Nutrition: direction is indirect and bidirectional. The salt is taken with food to improve tolerance and blunt post-dose urinary calcium, but calcium taken with meals reduces non-heme iron and zinc absorption from those meals. Practical point: the lower-iron meals of the day are the sensible pairing, with iron-rich meals two hours away.

  • Exercise: direction is potentially blunting, unquantified. Inhibition of ATP synthase and suppression of the growth pathway that drives muscle protein synthesis are the theoretical basis; against this, mice on the salt walked more yet failed a treadmill exhaustion test. Practical point: the cautious placement is away from the post-resistance-training window.

  • Stress management: direction is indirect. The proposed mechanism is anti-inflammatory rather than hormonal — interleukin-10 induction in mice — with no measured effect on cortisol or the stress axis in any species. Practical point: nothing about the protocol argues for or against any particular stress practice.

Monitoring Protocol & Defining Success

Because nothing about this compound produces a felt effect, monitoring is the only way to distinguish response from expenditure. The baseline chemistry panel used in practice captures both the mineral load and the pathway the compound is claimed to act on: albumin-corrected serum calcium, intact parathyroid hormone, 25-hydroxyvitamin D, serum phosphate, kidney filtration by both creatinine and cystatin C, a 24-hour urinary calcium, high-sensitivity C-reactive protein, red-cell magnesium, iron status, and an epigenetic-age measurement from a single provider. The calcium panel is then rechecked at six weeks to catch an early hypercalcaemic drift, the full panel repeated at six months, and the cadence moved to annual thereafter, with a 24-hour urinary calcium every one to two years. The epigenetic clock is retested no sooner than twelve months, since assay noise exceeds any plausible short-term change.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum calcium (albumin-corrected) 9.0–10.0 mg/dL (2.25–2.50 mmol/L) Detects excess from the mineral load Conventional upper limit is 10.5 mg/dL; draw fasting and pair with parathyroid hormone
24-hour urinary calcium Men below 250 mg/day; women below 200 mg/day Earliest stone signal, moves before serum calcium Collect on the usual diet and dose; conventional labs call up to 300 mg/day normal
Intact parathyroid hormone (the gland signal controlling blood calcium) 15–35 pg/mL Separates a supplement effect from undiagnosed hyperparathyroidism Conventional range runs to about 65 pg/mL; draw with a simultaneous calcium; morning, fasting
25-hydroxyvitamin D 40–60 ng/mL Governs how much added calcium is absorbed Conventional range starts at 30 ng/mL; higher levels amplify absorption and stone risk
Serum phosphate 3.0–4.0 mg/dL The salt binds dietary phosphate Fasting; a low-normal drift is expected and usually benign
Estimated glomerular filtration rate (calculated kidney filtering capacity), creatinine and cystatin C 90 mL/min/1.73 m² or above, and within 10% of own baseline Kidney handling of the calcium load Conventional cut-off is 60 mL/min/1.73 m²; creatinine-based estimates read falsely low in high-muscle-mass people, and cystatin C resolves this
High-sensitivity C-reactive protein Below 0.5 mg/L Tracks the inflammation pathway proposed in animals Conventional cut-off is 3.0 mg/L; repeat only when free of infection or recent hard training
Red-cell magnesium 5.0–6.5 mg/dL Calcium loading competes with magnesium status Serum magnesium is insensitive and stays normal until stores are badly depleted
Ferritin with transferrin saturation Ferritin 50–150 ng/mL; saturation 25–35% Calcium with meals blunts non-heme iron absorption Conventional ferritin range starts near 15–30 ng/mL; ferritin rises with inflammation, so read alongside high-sensitivity C-reactive protein
Epigenetic age (DNA methylation clock) No established target; track change against the individual’s own baseline The endpoint the human trial is powered on Assay noise spans several years; use the same provider, sample type and time of day

Qualitative markers worth tracking alongside the labs:

  • Grip strength and a timed sit-to-stand, since these are the functional secondary endpoints the human trial is collecting
  • Perceived energy and exercise recovery, recorded weekly rather than daily to smooth noise
  • Cognitive clarity and subjective sleep quality, as a check that nothing is being made worse
  • Skin, hair and nail condition, the phenotype most visibly changed in treated mice
  • Gastrointestinal comfort and stool consistency, the earliest and most likely adverse signal

Emerging Research

Research directions are framed for someone deciding whether to start, continue or stop a personal protocol, not for a population-level policy question.

  • ABLE, the pivotal human trial: NCT05706389 randomised 120 adults aged 40–60 with an elevated DNA methylation age to 1 gram of sustained-release salt or placebo for six months. Primary endpoint is change in methylation age; the protocol also collects grip and leg strength, arterial stiffness and aerobic capacity. Results are unpublished.

  • AEGIS, the surgical-resilience trial: NCT07031128 is a 250-patient, quadruple-blind Phase 4 study of 1 gram daily around coronary artery bypass grafting, with a primary composite of systemic inflammatory response syndrome plus organ dysfunction to day 90. It is the only trial powered on hard clinical events.

  • Aneurysm progression, a trial that could weaken the case: NCT04723888 follows 300 people with 39–49 mm abdominal aortic aneurysms. A null or adverse result in a calcification-prone vascular bed would directly test the protective mechanism proposed in animal work.

  • Independent replication has already failed: the Interventions Testing Program (Korstanje et al., 2026) found no lifespan effect in genetically heterogeneous mice starting at either 7 or 18 months, across three sites. This is the strongest counterweight to the original mouse result and remains unreconciled with it.

  • Small adjunct studies: NCT07114536, a 30-person phenotypic-age study of the calcium salt run by a supplement manufacturer, and NCT06445244, a 30-person academic trial of blood pressure and vessel function in hypertension. Both are small, so they will add signal rather than settle anything.

  • Ocular and organ-specific endpoints: NCT07269704, a completed 17-person early-phase study of the supplement in age-related eye disease, is notable because a cataract signal appeared in treated mice.

  • Observational epigenetic screening: Pabis and colleagues, 2026 screened 84 supplements in 4,260 adults and found the delayed-release form associated with lower biological age while plain alpha-ketoglutarate was not. Whether the formulation, the added vitamins or user selection explains that gap is the open question.

Conclusion

Calcium alpha-ketoglutarate is a stable salt of a molecule the body makes when turning food into energy, and which also partners enzymes that add and remove chemical marks on genes. Its long clinical record is real but narrow: lowering blood ammonia, binding phosphate in kidney failure, and limiting muscle breakdown after operations. The longevity case rests on animal feeding studies and on uncontrolled human datasets produced by the companies that sell the product and the biological-age test used to score it — a financial interest sitting directly on top of the most favourable numbers.

The best human evidence sits far from the longevity claim: in people on dialysis, two randomised comparisons show the salt lowers blood phosphate as well as standard binders do. Nearer the claim, a bone-breakdown marker fell in postmenopausal women with thinning bone, in a single trial where bone density itself did not clearly change. Anything more is animal work, now unreplicated in a large independent multi-site programme, or tracking of what supplement users report rather than testing against a placebo. The clearest quantified hazard belongs not to the alpha-ketoglutarate but to the calcium it carries, and that literature is itself split.

For someone who already runs biomarker testing and can hold total calcium inside recommended limits, the exposure is modest and the mechanism is coherent. For someone hoping the animal survival result transfers intact, the evidence does not currently support that expectation, and the trial that could change it has not reported.

Top - Benefits - Risks - Protocol